Retinitis pigmentosa 84

disease
On this page

Also known as RP84

Summary

Retinitis pigmentosa 84 (MONDO:0032604) is a disease caused by DHX38 (GenCC Strong), with 1 cohort gene.

At a glance

  • Causal gene: DHX38 (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameretinitis pigmentosa 84
Mondo IDMONDO:0032604
OMIM618220
DOIDDOID:0112141
UMLSC4748725
MedGen1648352
GARD0016311
Is cancer (heuristic)no

Also known as: RP84

Data availability: 21 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationinherited retinal dystrophyretinitis pigmentosaretinitis pigmentosa 84

Related subtypes (101): retinitis pigmentosa 6, cone-rod dystrophy 2, retinitis pigmentosa 1, retinitis pigmentosa 9, retinitis pigmentosa 10, dominant pericentral pigmentary retinopathy, late-adult onset retinitis pigmentosa, autosomal recessive pericentral pigmentary retinopathy, retinitis pigmentosa 3, retinitis pigmentosa 24, retinitis pigmentosa 23, retinitis pigmentosa 34, retinitis pigmentosa 2, retinitis pigmentosa Y-linked, retinitis pigmentosa 13, retinitis pigmentosa 12, retinitis pigmentosa 14, retinitis pigmentosa 11, retinitis pigmentosa 17, retinitis pigmentosa 18, retinitis pigmentosa 19, retinitis pigmentosa 22, retinitis pigmentosa 25, retinitis pigmentosa 28, retinitis pigmentosa 30, retinitis pigmentosa 7, retinitis pigmentosa 26, retinitis pigmentosa 32, retinitis pigmentosa 31, retinitis pigmentosa 35, retinitis pigmentosa 33, retinitis pigmentosa 36, retinitis pigmentosa 37, retinitis pigmentosa 41, retinitis pigmentosa 29, retinitis pigmentosa 46, retinitis pigmentosa 42, retinitis pigmentosa 50, retinitis pigmentosa 54, retinitis pigmentosa 51, retinitis pigmentosa 55, retinitis pigmentosa 56, retinitis pigmentosa 57, retinitis pigmentosa 58, cone-rod dystrophy 15, retinitis pigmentosa 4, retinitis pigmentosa 27, retinitis pigmentosa 49, retinitis pigmentosa 47, retinitis pigmentosa 45, retinitis pigmentosa 44, retinitis pigmentosa 20, retinitis pigmentosa 40, retinitis pigmentosa 39, retinitis pigmentosa 43, retinitis pigmentosa 48, retinitis pigmentosa 59, retinitis pigmentosa 38, retinitis pigmentosa 60, retinitis pigmentosa 61, retinitis pigmentosa 62, retinitis pigmentosa 63, cone-rod dystrophy 16, retinitis pigmentosa 66, retinitis pigmentosa with or without situs inversus, retinitis pigmentosa 67, retinitis pigmentosa 68, retinitis pigmentosa 69, retinitis pigmentosa 70, retinal dystrophy and obesity, retinitis pigmentosa 71, retinitis pigmentosa 72, retinitis pigmentosa 73, retinitis pigmentosa 74, retinitis pigmentosa 75, retinitis pigmentosa 76, retinitis pigmentosa 77, retinitis pigmentosa 92, retinitis pigmentosa 93, retinitis pigmentosa 83, retinitis pigmentosa 85, retinitis pigmentosa 86, retinitis pigmentosa 87 with choroidal involvement, retinitis pigmentosa 88, retinitis pigmentosa 90, retinitis pigmentosa 81, retinitis pigmentosa 78, retinitis pigmentosa 79, retinitis pigmentosa 80, retinitis pigmentosa 94, variable age at onset, retinitis pigmentosa 53, retinitis pigmentosa 65, retinitis pigmentosa 64, retinitis pigmentosa 95, retinitis pigmentosa 96, retinitis pigmentosa 97, retinitis pigmentosa 98, retinitis pigmentosa 99, retinitis pigmentosa 100, retinitis pigmentosa 101, retinitis pigmentosa 7, digenic

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

21 retrieved; paginated sample, class counts are floors:

11 uncertain significance, 7 benign, 1 benign/likely benign, 1 not provided, 1 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
592160NM_014003.4(DHX38):c.971G>A (p.Arg324Gln)DHX38Likely pathogeniccriteria provided, single submitter
1001576NM_014003.4(DHX38):c.3193G>C (p.Asp1065His)DHX38Uncertain significancecriteria provided, single submitter
1009284NM_014003.4(DHX38):c.716A>G (p.Tyr239Cys)DHX38Uncertain significancecriteria provided, multiple submitters, no conflicts
1013901NM_014003.4(DHX38):c.2065G>T (p.Ala689Ser)DHX38Uncertain significancecriteria provided, multiple submitters, no conflicts
1399641NM_014003.4(DHX38):c.605A>G (p.His202Arg)DHX38Uncertain significancecriteria provided, multiple submitters, no conflicts
140595NM_014003.4(DHX38):c.995G>A (p.Gly332Asp)DHX38Uncertain significancecriteria provided, single submitter
2122159NM_014003.4(DHX38):c.2108A>C (p.His703Pro)DHX38Uncertain significancecriteria provided, single submitter
840809NM_014003.4(DHX38):c.923C>T (p.Thr308Met)DHX38Uncertain significancecriteria provided, multiple submitters, no conflicts
842571NM_014003.4(DHX38):c.2831G>A (p.Arg944Gln)DHX38Uncertain significancecriteria provided, multiple submitters, no conflicts
850322NM_014003.4(DHX38):c.2011-3C>ADHX38Uncertain significancecriteria provided, single submitter
858580NM_014003.4(DHX38):c.55G>A (p.Asp19Asn)DHX38Uncertain significancecriteria provided, multiple submitters, no conflicts
998968NM_014003.4(DHX38):c.889C>T (p.Arg297Cys)DHX38Uncertain significancecriteria provided, single submitter
1167005NM_014003.4(DHX38):c.2487+14T>CDHX38Benigncriteria provided, multiple submitters, no conflicts
1167324NM_014003.4(DHX38):c.147C>G (p.Leu49=)DHX38Benigncriteria provided, multiple submitters, no conflicts
1167325NM_014003.4(DHX38):c.418C>A (p.Arg140=)DHX38Benigncriteria provided, multiple submitters, no conflicts
1167326NM_014003.4(DHX38):c.1308T>C (p.Ala436=)DHX38Benigncriteria provided, multiple submitters, no conflicts
1167327NM_014003.4(DHX38):c.1698G>A (p.Thr566=)DHX38Benigncriteria provided, multiple submitters, no conflicts
1168651NM_014003.4(DHX38):c.2316C>A (p.Ala772=)DHX38Benigncriteria provided, multiple submitters, no conflicts
1170141NM_014003.4(DHX38):c.2380-20T>CDHX38Benigncriteria provided, multiple submitters, no conflicts
1170574NM_014003.4(DHX38):c.1386+17C>TDHX38Benign/Likely benigncriteria provided, multiple submitters, no conflicts
1802696NM_014003.4(DHX38):c.3056del (p.Lys1019fs)DHX38not providedno classification provided

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
DHX38StrongAutosomal recessiveretinitis pigmentosa 845

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
DHX38Orphanet:791Retinitis pigmentosa

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
DHX38HGNC:17211ENSG00000140829Q92620Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
DHX38Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16Probable ATP-binding RNA helicase.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
DHX38Other/UnknownnoHelicase_C-like, DNA/RNA_helicase_DEAH_CS, Helicase-assoc_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
left ovary1
right ovary1
sural nerve1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
DHX38250ubiquitousmarkersural nerve, left ovary, right ovary

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
DHX383,449

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
DHX38Q926204

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 4. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
mRNA 3’-end processing1196.9×0.013DHX38
Transport of Mature mRNA derived from an Intron-Containing Transcript1152.3×0.013DHX38
mRNA Splicing - Major Pathway154.6×0.022DHX38
Dengue Virus-Host Interactions145.7×0.022DHX38

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
mRNA splicing, via spliceosome191.6×0.011DHX38

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
DHX3800

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1DHX38

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
DHX380

Clinical trials & evidence

Clinical trials

Clinical trials: 0.